Carba1 is a bifunctional Carbazole derivative that activates nicotinamide phosphoribosyltransferase ( NAMPT ) and enhances NAD biosynthesis. Carba1 binds to colchicine site of tubulin, enhancing the anti-tumor effect of various chemotherapy drugs, such as Paclitaxel. Carba1 exerts neuroprotective effect and can regulate cell energy metabolism. Carba1 can be used for the researches of cancer and chemotherapy-induced peripheral neuropathy (CIPN) [1].
In Vivo, Carba1 (50 mg/kg; i.p.; on days 0, 1, 2, 4, 7, 9) prevents tactile allodynia and neurodegeneration in Paclitaxel-induced rats neuropathy model[1]. Carba1 (60 mg/kg; i.v.; every 2 days for 10 days) does not promote tumor growth and does not inhibit the antitumor activity of Paclitaxel in tumor growth modeling[1].
In Vitro, Carba1 (12 μM; 72 h) synergizes with Paclitaxel, Docetaxel, nab-Paclitaxel, and Epothilone-B to inhibit HeLa cell viability, reducing their GI50 values by 2.6, 3.8, 1.8 and 4.4 folds[1]. Carba1 (1-20 μM; 60 mins) enhances NAMPT activity in HeLa cells[1]. Carba1 (12 μM; 72 h) protects adult mouse DRG neurons from axonal degeneration induced by Paclitaxel, Cisplatin and Bortezomib, reducing the degeneration index[1]. Carba1 (1-10 μM; 24 h) protects against Cisplatin-induced neurotoxicity and myelination impairment in rat DRG neurons[1]. Carba1 (12 μM, 2 h) regulates HeLa cell metabolism, increasing lactate, glutamate, ATP, and GTP levels, decreasing NAD+ levels, and enhancing glycolysis and glutaminolysis[1].
References:
[1]. Bosc L, et al. Preventing neuropathy and improving anticancer chemotherapy with a carbazole-based compound. Sci Adv. 2025 Oct 31;11(44):eadw6328.
In Vivo, Carba1 (50 mg/kg; i.p.; on days 0, 1, 2, 4, 7, 9) prevents tactile allodynia and neurodegeneration in Paclitaxel-induced rats neuropathy model[1]. Carba1 (60 mg/kg; i.v.; every 2 days for 10 days) does not promote tumor growth and does not inhibit the antitumor activity of Paclitaxel in tumor growth modeling[1].
In Vitro, Carba1 (12 μM; 72 h) synergizes with Paclitaxel, Docetaxel, nab-Paclitaxel, and Epothilone-B to inhibit HeLa cell viability, reducing their GI50 values by 2.6, 3.8, 1.8 and 4.4 folds[1]. Carba1 (1-20 μM; 60 mins) enhances NAMPT activity in HeLa cells[1]. Carba1 (12 μM; 72 h) protects adult mouse DRG neurons from axonal degeneration induced by Paclitaxel, Cisplatin and Bortezomib, reducing the degeneration index[1]. Carba1 (1-10 μM; 24 h) protects against Cisplatin-induced neurotoxicity and myelination impairment in rat DRG neurons[1]. Carba1 (12 μM, 2 h) regulates HeLa cell metabolism, increasing lactate, glutamate, ATP, and GTP levels, decreasing NAD+ levels, and enhancing glycolysis and glutaminolysis[1].
References:
[1]. Bosc L, et al. Preventing neuropathy and improving anticancer chemotherapy with a carbazole-based compound. Sci Adv. 2025 Oct 31;11(44):eadw6328.